U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06917742) titled 'A Study of CPTX2309 in Healthy Participants' on March 24.
Brief Summary: The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: CPTX2309
Single Escalating Dose of CPTX2309. CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
DRUG: CPTX2309
Multiple Escalating Dose of CPTX2309.CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
Recruitment...